Cullinan Oncology Llc Stock Buy Hold or Sell Recommendation
| CGEM Stock | USD 8.54 0.02 0.23% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cullinan Oncology LLC is 'Strong Sell'. The recommendation algorithm takes into account all of Cullinan Oncology's available fundamental, technical, and predictive indicators you will find on this site.
Check out Cullinan Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Cullinan and provide practical buy, sell, or hold advice based on investors' constraints. Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Cullinan |
Execute Cullinan Oncology Buy or Sell Advice
The Cullinan recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cullinan Oncology LLC. Macroaxis does not own or have any residual interests in Cullinan Oncology LLC or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cullinan Oncology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cullinan Oncology Trading Alerts and Improvement Suggestions
| Cullinan Oncology generated a negative expected return over the last 90 days | |
| Cullinan Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (153.16 M) with profit before overhead, payroll, taxes, and interest of 18.94 M. | |
| Cullinan Oncology LLC currently holds about 611 M in cash with (134.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cullinan Oncology has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Cullinan Oncology stock hits 52-week low at 8.99 - Investing.com India |
Cullinan Oncology Returns Distribution Density
The distribution of Cullinan Oncology's historical returns is an attempt to chart the uncertainty of Cullinan Oncology's future price movements. The chart of the probability distribution of Cullinan Oncology daily returns describes the distribution of returns around its average expected value. We use Cullinan Oncology LLC price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cullinan Oncology returns is essential to provide solid investment advice for Cullinan Oncology.
| Mean Return | -0.63 | Value At Risk | -6.27 | Potential Upside | 4.98 | Standard Deviation | 3.12 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cullinan Oncology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cullinan Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Cullinan Oncology, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Cullinan Oncology LLC back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Vr Adviser, Llc | 2024-12-31 | 1.4 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | Kynam Capital Management, Lp | 2024-12-31 | 1.3 M | Geode Capital Management, Llc | 2024-12-31 | 1.2 M | Siren, L.l.c. | 2024-12-31 | 1.2 M | Braidwell Lp | 2024-12-31 | 1.2 M | Nextech Invest Ag | 2024-12-31 | 1.1 M | Orbimed Advisors, Llc | 2024-09-30 | 1.1 M | Adage Capital Partners Gp Llc | 2024-12-31 | 1 M | Mpm Oncology Impact Management Lp | 2024-12-31 | 7.6 M | Bvf Inc | 2024-12-31 | 5.8 M |
Cullinan Oncology Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Capital Expenditures | 10K | 589.2K | 1.1M | 208K | 239.2K | 222.1K | |
| Change In Cash | 104.9M | (108.4M) | 96.4M | (57.7M) | (51.9M) | (49.3M) | |
| Net Income | (59.5M) | (67.5M) | 109.2M | (153.2M) | (137.8M) | (131.0M) | |
| Change To Netincome | (445K) | 15.1M | 24.4M | 28.0M | 32.2M | 33.8M | |
| End Period Cash Flow | 168.2M | 59.8M | 156.2M | 98.4M | 113.2M | 98.6M | |
| Investments | (6.9M) | (333.8M) | (25.0M) | 35.8M | 32.2M | 33.8M | |
| Free Cash Flow | (29.8M) | (44.0M) | (127.8M) | (134.5M) | (121.0M) | (115.0M) | |
| Depreciation | 62K | 53K | 93K | 310K | 356.5K | 374.3K | |
| Other Non Cash Items | 7.6M | 67K | (275.1M) | (11.5M) | (10.4M) | (10.9M) |
Cullinan Oncology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cullinan Oncology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cullinan Oncology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cullinan stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.65 | |
β | Beta against Dow Jones | 0.38 | |
σ | Overall volatility | 3.17 | |
Ir | Information ratio | -0.21 |
Cullinan Oncology Volatility Alert
Cullinan Oncology LLC exhibits very low volatility with skewness of -0.07 and kurtosis of 0.56. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cullinan Oncology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cullinan Oncology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cullinan Oncology Fundamentals Vs Peers
Comparing Cullinan Oncology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cullinan Oncology's direct or indirect competition across all of the common fundamentals between Cullinan Oncology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cullinan Oncology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cullinan Oncology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Cullinan Oncology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cullinan Oncology to competition |
| Fundamentals | Cullinan Oncology | Peer Average |
| Return On Equity | -0.27 | -0.31 |
| Return On Asset | -0.2 | -0.14 |
| Current Valuation | (77.2 M) | 16.62 B |
| Shares Outstanding | 58.23 M | 571.82 M |
| Shares Owned By Insiders | 4.47 % | 10.09 % |
| Shares Owned By Institutions | 95.53 % | 39.21 % |
| Number Of Shares Shorted | 8.73 M | 4.71 M |
| Price To Earning | 5.23 X | 28.72 X |
| Price To Book | 0.79 X | 9.51 X |
| Price To Sales | 26.88 X | 11.42 X |
| Gross Profit | 18.94 M | 27.38 B |
| EBITDA | (190.34 M) | 3.9 B |
| Net Income | (153.16 M) | 570.98 M |
| Cash And Equivalents | 611 M | 2.7 B |
| Cash Per Share | 13.40 X | 5.01 X |
| Total Debt | 3.59 M | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 10.04 X | 2.16 X |
| Book Value Per Share | 10.80 X | 1.93 K |
| Cash Flow From Operations | (134.28 M) | 971.22 M |
| Short Ratio | 17.60 X | 4.00 X |
| Earnings Per Share | (2.84) X | 3.12 X |
| Target Price | 33.89 | |
| Number Of Employees | 85 | 18.84 K |
| Beta | -0.16 | -0.15 |
| Market Capitalization | 498.43 M | 19.03 B |
| Total Asset | 484.18 M | 29.47 B |
| Retained Earnings | (200.86 M) | 9.33 B |
| Working Capital | 452.05 M | 1.48 B |
| Net Asset | 484.18 M |
Note: Acquisition by Mary Fenton of 60000 shares of Cullinan Oncology subject to Rule 16b-3 [view details]
Cullinan Oncology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cullinan . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 8.54 | |||
| Day Typical Price | 8.54 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) | |||
| Relative Strength Index | 34.5 |
About Cullinan Oncology Buy or Sell Advice
When is the right time to buy or sell Cullinan Oncology LLC? Buying financial instruments such as Cullinan Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cullinan Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Care ETFs Thematic Idea Now
Health Care ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Health Care ETFs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Care ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cullinan Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.